News und Analysen
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important U.S. and European regulatory updates for isaralgagene civaparvovec, or ST-920, its wholly owned gene
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Owens & Minor Announces Fourth Quarter 2023 Earnings Release Date and Conference Call
Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the fourth quarter of 2023 on Tuesday, February 20, 2024, before trading begins on the New York Stock Exchange.
The Company
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.
Fourth Quarter 2023 Financial Highlights:
-
Revenue grew 27%
Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products
Agilent Technologies Inc. (NYSE: A) announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery &
Agilent to Participate in TD Cowen Health Care Conference
Agilent Technologies Inc. (NYSE: A) today announced that CFO Bob McMahon will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference in Boston, Massachusetts, on Monday
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2023 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2023 results on Tuesday, February 27, 2024, after the close of the market. Acadia
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
Humana Releases Results from Innovative Health Literacy and Healthcare Discrimination Screenings Pilot
Humana Inc. (NYSE: HUM), a leading U.S. health insurer and healthcare services company, continues to make strides in advancing health equity by releasing the findings of its new pilot study
EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.
Highlights and Outlook
-
Q4 sales grew 14 percent to $1.53 billion; constant currency1
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it
Simulations Plus to Participate in Upcoming Healthcare Conferences
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or
Premier, Inc. Reports Fiscal-Year 2024 Second-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2024 second quarter ended December 31, 2023.
"Our
Premier, Inc. Completes Strategic Review Process
Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-driven healthcare improvement company, today announced that the Company’s Board of Directors has concluded its
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “Change the Odds™: Uniting to Improve Cancer Outcomes,” a three-year initiative to bridge the gap in
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a
EQS-News: MPH Health Care AG sells 1.5 million shares in its investment M1 Kliniken AG to its Management Board members
EQS-News: Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard